Short Interest in Ralliant Corporation (NYSE:RAL) Expands By 32.4%

Ralliant Corporation (NYSE:RAL) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 2,784,414 shares, a growth of 32.4% from the November 30th total of 2,102,958 shares. Based on an average trading volume of 1,453,677 shares, the days-to-cover ratio is currently 1.9 days. Currently, 2.5% of the shares of the company are sold short. Currently, 2.5% of the shares of the company are sold short. Based on an average trading volume of 1,453,677 shares, the days-to-cover ratio is currently 1.9 days.

Analyst Ratings Changes

Several research firms have recently issued reports on RAL. Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and increased their price objective for the company from $53.00 to $61.00 in a report on Monday, December 8th. Royal Bank Of Canada raised their price objective on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Truist Financial began coverage on shares of Ralliant in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective on the stock. Oppenheimer raised their price objective on Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a research report on Monday. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.89.

Ralliant Stock Performance

Shares of NYSE RAL traded down $0.09 during midday trading on Tuesday, reaching $51.16. 887,669 shares of the company traded hands, compared to its average volume of 1,354,990. The firm has a market capitalization of $5.77 billion and a price-to-earnings ratio of 40.28. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. The business’s 50-day moving average price is $47.99. Ralliant has a 12 month low of $40.70 and a 12 month high of $55.08.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.02. The firm had revenue of $529.10 million for the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Ralliant’s payout ratio is currently 15.75%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Westfuller Advisors LLC acquired a new position in Ralliant during the 3rd quarter worth approximately $26,000. Palisade Asset Management LLC bought a new position in shares of Ralliant in the 3rd quarter valued at $26,000. ST Germain D J Co. Inc. acquired a new stake in shares of Ralliant during the 2nd quarter valued at $27,000. Manchester Capital Management LLC bought a new stake in Ralliant during the 2nd quarter worth $29,000. Finally, UMB Bank n.a. bought a new stake in Ralliant during the 3rd quarter worth $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.